
Medincell SA
PAR:MEDCL


to continue MEDCL research
to continue MEDCL research
You've reached your weekly stock limit.
Sign UpMedincell SA?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
12.84
18.64
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Medincell SA hold over its rivals?
What risks and challenges
does Medincell SA face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Medincell SA.
Provide an overview of the primary business activities
of Medincell SA.
What unique competitive advantages
does Medincell SA hold over its rivals?
What risks and challenges
does Medincell SA face in the near future?
Has there been any significant insider trading activity
in Medincell SA recently?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Medincell SA.
Provide P/S
for Medincell SA.
Provide P/E
for Medincell SA.
Provide P/OCF
for Medincell SA.
Provide P/FCFE
for Medincell SA.
Provide P/B
for Medincell SA.
Provide EV/S
for Medincell SA.
Provide EV/GP
for Medincell SA.
Provide EV/EBITDA
for Medincell SA.
Provide EV/EBIT
for Medincell SA.
Provide EV/OCF
for Medincell SA.
Provide EV/FCFF
for Medincell SA.
Provide EV/IC
for Medincell SA.
Show me price targets
for Medincell SA made by professional analysts.
What are the Revenue projections
for Medincell SA?
How accurate were the past Revenue estimates
for Medincell SA?
What are the Net Income projections
for Medincell SA?
How accurate were the past Net Income estimates
for Medincell SA?
What are the EPS projections
for Medincell SA?
How accurate were the past EPS estimates
for Medincell SA?
What are the EBIT projections
for Medincell SA?
How accurate were the past EBIT estimates
for Medincell SA?
Compare the revenue forecasts
for Medincell SA with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Medincell SA and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Medincell SA against its competitors.
Analyze the profit margins
(gross, operating, and net) of Medincell SA compared to its peers.
Compare the P/E ratios
of Medincell SA against its peers.
Discuss the investment returns and shareholder value creation
comparing Medincell SA with its peers.
Analyze the financial leverage
of Medincell SA compared to its main competitors.
Show all profitability ratios
for Medincell SA.
Provide ROE
for Medincell SA.
Provide ROA
for Medincell SA.
Provide ROIC
for Medincell SA.
Provide ROCE
for Medincell SA.
Provide Gross Margin
for Medincell SA.
Provide Operating Margin
for Medincell SA.
Provide Net Margin
for Medincell SA.
Provide FCF Margin
for Medincell SA.
Show all solvency ratios
for Medincell SA.
Provide D/E Ratio
for Medincell SA.
Provide D/A Ratio
for Medincell SA.
Provide Interest Coverage Ratio
for Medincell SA.
Provide Altman Z-Score Ratio
for Medincell SA.
Provide Quick Ratio
for Medincell SA.
Provide Current Ratio
for Medincell SA.
Provide Cash Ratio
for Medincell SA.
What is the historical Revenue growth
over the last 5 years for Medincell SA?
What is the historical Net Income growth
over the last 5 years for Medincell SA?
What is the current Free Cash Flow
of Medincell SA?
Discuss the annual earnings per share (EPS)
trend over the past five years for Medincell SA.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
FR |
![]() |
Medincell SA
PAR:MEDCL
|
544.3m EUR | -31.3 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
744B USD | 36 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
362.6B USD | 12.2 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK | 14.3 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
205.8B CHF | 9.3 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
186.3B CHF | 10.4 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
163.3B GBP | 130.8 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
199.5B USD | 8.5 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD | 261.3 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
135.8B USD | 7.4 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
FR |
![]() |
Medincell SA
PAR:MEDCL
|
Average EV/EBITDA:
433.7
|
N/A | N/A | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
36
|
30%
|
1.2 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 846.3
|
36%
|
106.8 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
12.2
|
7%
|
1.7 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
14.3
|
13%
|
1.1 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
9.3
|
5%
|
1.9 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
10.4
|
5%
|
2.1 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
130.8
|
10%
|
13.1 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
8.5
|
8%
|
1.1 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
261.3
|
N/A | N/A |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
7.4
|
2%
|
3.7 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.